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Abstract
The class-3 semaphorins (sema3s) include seven family members. Six of them bind to neuropilin-1 (np1) or neuropilin-2
(np2) receptors or to both, while the seventh, sema3E, binds to the plexin-D1 receptor. Sema3B and sema3F were previously
characterized as tumor suppressors and as inhibitors of tumor angiogenesis. To determine if additional class-3 semaphorins
such as sema3A, sema3D, sema3E and sema3G possess anti-angiogenic and anti-tumorigenic properties, we expressed the
recombinant full length semaphorins in four different tumorigenic cell lines expressing different combinations of class-3
semaphorin receptors. We show for the first time that sema3A, sema3D, sema3E and sema3G can function as potent anti-
tumorigenic agents. All the semaphorins we examined were also able to reduce the concentration of tumor associated
blood vessels although the potencies of the anti-angiogenic effects varied depending on the tumor cell type. Surprisingly,
there was little correlation between the ability to inhibit tumor angiogenesis and their anti-tumorigenic activity. None of the
semaphorins inhibited the adhesion of the tumor cells to plastic or fibronectin nor did they modulate the proliferation of
tumor cells cultured in cell culture dishes. However, various semaphorins were able to inhibit the formation of soft agar
colonies from tumor cells expressing appropriate semaphorin receptors, although in this case too the inhibitory effect was
not always correlated with the anti-tumorigenic effect. In contrast, the anti-tumorigenic effect of each of the semaphorins
correlated very well with tumor cell expression of specific signal transducing receptors for particular semaphorins. This
correlation was not broken even in cases in which the tumor cells expressed significant concentrations of endogenous
semaphorins. Our results suggest that combinations of different class-3 semaphorins may be more effective than single
semaphorins in cases in which tumor cells express more than one type of semaphorin receptors.
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Introduction
The neuropilin-1 (np1) and the neuropilin-2 (np2) receptors
were originally characterized as receptors for axon guidance
factors of the class-3 semaphorin (sema3) family [1]. It was
subsequently realized that neuropilins are also expressed by
endothelial cells and by many types of cancer cells [2]. Neuropilins
function in addition as receptors for several angiogenic factors
including heparin binding forms of VEGF and hepatocyte growth
factor/scatter factor (HGF/SF) and enhance their pro-angiogenic
activity [3–6]. These studies indicate that neuropilins may be
targets for anti-angiogenic therapy. Indeed, antibodies directed
against np1 and np2 were recently found to inhibit tumor
progression [7,8].
Most of the sema3s, with the exception of sema3E which binds
to Plexin-D1 (plexD1) [9], bind to one of the two neuropilins or to
both. Neuropilins form functional semaphorin receptors by
associating with members of the plexin receptor family in which
neuropilins bind semaphorins and the plexins function as the
signal transducing elements [10,11]. The four type-A plexins as
well as plexD1 were found to participate in neuropilin mediated
signal transduction [10–12]. The semaphorins sema3B and
sema3F were characterized as tumor suppressor genes indicating
that additional semaphorins may also possess anti-tumorigenic
properties [13,14]. The identification of neuropilins in endothelial
cells suggested that class-3 semaphorins may also regulate
angiogenesis. Indeed, the np2 agonist sema3F functions as a
repellant of endothelial cells. It also induces apoptosis of
endothelial cells, and inhibits tumor angiogenesis and tumor
progression [15,16]. The np1 agonist sema3A also inhibits
angiogenesis [17] but it is as yet unknown whether it can inhibit
tumor angiogenesis and tumor progression. Likewise, the plexD1
agonist sema3E was found to inhibit the invasion of blood vessels
into somites during embryonic development [9] suggesting that
sema3E too may function as an anti-angiogenic agent.
The expression of neuropilins and plexins by many types of
tumor cells indicates that semaphorins may be able to affect tumor
cells directly. Indeed, sema3F and sema3B have been found to
inhibit the adhesion, migration and proliferation of several types of
lung cancer derived tumor cells [13,14,16,18]. It follows that
semaphorins such as sema3F probably inhibit angiogenesis and
tumor cell proliferation simultaneously and may also affect in
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However, it is unclear which of these mechanisms is the primary
mechanism used by semaphorins such as sema3F to inhibit tumor
development. It is also unclear whether additional sema3s possess
anti-angiogenic and anti-tumorigenic properties. We report that
four additional class-3 semaphorins which have not yet been found
to possess anti-tumorigenic properties, sema3A, sema3D, sema3E,
and sema3G possess anti-tumorigenic properties. Furthermore, all
these semaphorins with the exception of sema3E strongly reduce
the density of blood vessels in tumors. However, we find that
inhibition of tumor development by class-3 semaphorins is strongly
correlated with the expression of appropriate semaphorin
receptors by the tumor cells and that there is a much poorer
correlation between their ability to inhibit angiogenesis and their
effects on tumor development.
Materials and Methods
Materials
Antibodies against b-actin and myc and FLAG epitope tags, as
well as chemicals were from Sigma (St. Louis, MI). Media and sera
for cell culture were from Biological-Industries Inc. (Kibbutz Beth-
Haemek, Israel). Fugene-6 was from Roche Ltd (Switzerland).
Antibodies against np1 and np2 were purchased from Santa-Cruz
inc. (San-Diego, CA). The cDNAs encoding different semaphorins
were subcloned into the NSPI-CMV-MCS-myc-His lentiviral
expression vector containing SV40 promoter driving Puromycin
selection marker. This vector was kindly given to us by Dr.
Aaronson (Mount Sinai Hospital, NY). Partial cDNAs encoding
sema3E were kindly given to us by Dr. Claus Christensen (Institute
of cancer biology, Copenhagen, Denmark). Antibodies against
CD-31 were from BD biosciences Pharmingen. The cDNA’s
encoding sema3F and sema3A were donated by Dr. Mark Tessier-
Lavigne (University of California, San Francisco, CA) and by Drs.
David Ginty and Alex Kolodkin (Johns Hopkins University,
Baltimore, MD). The PerfectPure RNA reverse PCR kit was from
5-Prime (Gaithersburg, MD).
Primers
The following specific primers were used to follow the expression
of different plexins and semaphorins in the cancer cell lines. Plexin-
A1: 59-ctgctggtcatcgtggctgtgct 59-gggcccttctccatctgctgcttga. Plexin-
A2: 59-gtgcccaccaactgtgcctgtcctg 59-tcagcgatgatgtattcccctggga.
Plexin-A3: 59-tcttgctctcgaggttcttct 59-acatgccaagtgatcaacgac.
Plexin-A4: 59-acggtccatcccaacaatatc 59-ccacgccagcaaccttgacat.
Plexin-D1: 59-gtccatctaccagggcttct 59-ctggatgtaggactcggtga. Se-
ma3A: 59-aacgggggcttttcatcc 59-cccttctcacatcactcatgct. Sema3D:
59-ggctgctgaggatcgaaggac 59-atgtgtgtggaactggagca. Sema3E: 59-
gggttacttactggagctttgg 59-gtcatgctcagtgcggatatg. Sema3F: 59-
gtgctgcccaaggatgacca 59-cttgttggcattggagttgaacc. Sema3G: 59-aacg-
cagagctggccgagga 59-ccggacccacctgcta. Actin: 59-tgacggggtcaccca-
cactgtgcccatcta 59-ctagaagcattgcggtggacgatggaggg.
Expression plasmids
All the class-3 semaphorin cDNAs were sub-cloned into the
NSPI-CMV-myc-his lentiviral expression vector. The sema3G
cDNA was cloned from HUVEC mRNA using RT-PCR. The
sema3D cDNA was cloned using RT-PCR from HUVEC cells
treated with 30 ng/ml of VEGF for 6 hours. cDNA’s containing
the myc epitope tag were added in frame upstream to the stop
codon of sema3D, sema3E, sema3F and sema3G. A FLAG
epitope tag was added upstream to the stop codon of sema3A as
described [19].
Generation of recombinant lentiviruses and letiviral
mediated infection of cells
HEK293-T cells were seeded in 100 mm tissue culture dishes
(2.5610
6 cells/dish). A day after seeding, the cells were co-
transfected with the appropriate lentiviral expression plasmid
(8mg), with the packaging vector pCMVdR8.91 (5 mg), and with a
plasmid encoding the vesicular stomatitis virus coat envelope
pMD2-VSVG (2 mg) using Fugene-6 according to the instructions
of the vendor. Conditioned medium containing infective lentiviral
particles was collected 48 hours and 72 hours post transfection.
Following addition of polybrene (8 mg/ml) to the conditioned
medium it was incubated 8 hours with target cells.
Cell lines
Mycoplasma free MDA-MB-231, MDA-MB-435, MDA-MB-
468 and MCF7 cancer cells were obtained from the ATCC. The
cells were cultured in DMEM containing 4.5 mg/ml glucose
supplemented with 10% FCS and antibiotics. HUVEC, PAE,
HEK293 and HEK293-T cells were cultured as previously
described [15]. HUVEC were used between passages 3–7.
Animal experiments
All the animal experiments were approved by the institutional
committee for animal studies according to the NIH guidelines
(license IL-095-10-2007).
In-vivo tumor formation assays
Cells expressing semaphorins or control cells infected with
empty lentiviral vectors were implanted (5610
6/mouse) into the
mammary fat pads of 4–6 week old balb\c nu/nu female mice
(Harlan laboratories). In most experiments we used groups of 9
animals/experiment. The tumors were measured twice a week
using a caliper. The tumor volume (V) was determined using the
formula, V=0.526A
26B in which A is the short diameter and B
the long. When MDA-MB-231 tumors reached an average volume
of 200–300 mm
3, they were excised and weighted. Each
experiment was repeated at least twice. Estrogen pellets were
used in experiments in which the development of tumors from
MCF-7 cells was determined as previously described [20].
Immunohistochemistry
Tumors were embedded in OCT and frozen in 2-methylbutane
cooled by liquid nitrogen. They were then sectioned into 30 mm
thick sections using a cryostat. Sections were blocked with cold
acetone, reacted with an antibody directed against the endothelial
marker CD-31, counterstained with hematoxilin and photo-
graphed. Eight different microscopic fields derived from different
sections of three different tumors were photographed. These
photographs were taken from areas in which the density of blood
vessels was highest (hot spot method) [21,22]. The area of the
blood vessels in fields of equal area was quantified using the Image
Pro Plus software.
Western Blots
Cell lysates were prepared and the concentration of protein
determined as previously described [19]. To determine the
concentration of secreted sema3s in conditioned mediums of the
various cell lines, cells were seeded in 12 well dishes at a
concentration of 2610
5 cells/well. The cells were incubated for
48 hours in 0.4 ml of serum-free medium. Aliquots of equal volume
were examined using western blot analysis for the presence of
sema3s using antibodies directed against the appropriate tags as
previously described [19] and the densitometry analysis was
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semaphorins did not affect the proliferation rate or the survival of
the different semaphorin producing cells (data not shown).
Proliferation assays
Tumor cells (10
4 cells/well) were seeded in triplicate in 24 well
dishes. Adherent cells were trypsinized and counted every
24 hours for 4 days, using a coulter counter.
Adhesion assays
In cell adhesion experiments we used uncoated 12 well cell
culture dishes as well as non-adhesive 12 well dishes coated with
fibronectin (5 ml/ml). Tumor cells (10
5 cells/well) were seeded in
triplicates in growth media. The cells were washed twice with PBS,
trypsinized to release adherent cells, and counted with a coulter
counter. The cells were counted 5, 10, 20 and 45 minutes after
they were seeded. The percentage of adherent cells relative to the
number of seeded cells was then calculated and plotted. The time
required for the adherence of 50% of the seeded cells was used as a
measure to compare the adhesive properties of control and
semaphorin expressing cells.
Endothelial cells repulsion assay
Cell repulsion assays were performed essentially as previously
described [19].
Soft-agar colony formation assay
A layer of agar containing 2 ml of 0.5% low melting agar (Bio-
Rad) dissolved in growth media was poured into wells of a 6 well
cell culture dish and allowed to set at 4uC for 20 minutes. A
second layer (1ml) containing 0.3% of low melting agar dissolved
in growth media containing cells (3610
3 cells/ml) was placed on
top of the first layer and allowed to set at 4uC for 20 minutes.
Growth medium (2 ml) was added on top of the second layer and
the cells were incubated in a humidified incubator at 37uC for 21
days. Medium was changed twice a week. At the end of the
experiment, colonies were stained for 1 hr with 0.005% crystal
violet, and incubated with PBS overnight to remove excess crystal
violet. The colonies were photographed and colonies with at least
one diameter of 150 mm within photographic fields were chosen.
The Image-pro morphometric software was then used to measure
the area of each of these colonies. Their average area and statistics
were then performed using the Microsoft excel software.
Statistical analysis
Statistical analysis was performed using the unpaired data with
unequal variance student’s T-test. Error bars represent the
standard error of the mean. Statistical significance is presented
in the following manner: *p,0.05, **p,0.01 and ***p,0.001.
Results
Expression patterns of class-3 semaphorins and class-3
semaphorin receptors in different tumorigenic cell lines
Semaphorins may affect the development of tumors by directly
affecting the behavior of tumor cells or indirectly by affecting
angiogenesis or the behavior of stromal cells. To find out if the
class-3 semaphorins sema3A, sema3D, sema3E, sema3F and
sema3G can inhibit the formation of tumors from cancer cells by
directly influencing tumor cell behavior, we first determined the
expression patterns of known sema3 receptors in different cancer
cell lines. We found that MDA-MB-231 breast cancer derived cells
express predominantly np1 [4], a receptor for sema3A and
sema3D, but very little np2 if at all. MDA-MB-435 melanoma
cells express predominantly np2, a receptor for sema3F and
sema3G and very little if any np1 (Fig. 1A). MCF-7 breast cancer
cells express np1 but not np2. The concentration of np1 in MCF-7
cells is about three folds lower as compared to MDA-MB-231 cells
(Fig. 1, A–B). MDA-MB-468 breast cancer cells differ from the
other cell lines since they do not express neuropilins (Fig. 1A).
Because of their short intracellular domains neuropilins do not
transduce sema3 signals independently but form complexes with
plexins in which the plexins serve as the signal transducing
elements [10,11]. Good antibodies to plexins are not yet readily
available so we compared the expression of mRNA encoding
various plexins known to transduce class-3 semaphorins signals
qualitatively using RT-PCR as an indication for possible protein
expression. All four cell lines expressed the plexA1 mRNA and all
but the MDA-MB-468 cells also expressed the plexA2 mRNA.
None of these cell lines expressed the plexA4 mRNA and only the
MCF-7 cells expressed the plexA3 mRNA (Fig. 1, B–C). The
mRNA encoding the sema3E receptor PlexD1 was expressed in
MDA-MB-231 and MCF-7 cells while MDA-MB-435 cells seem
to express a lower concentration of PlexD1 mRNA (Fig. 1C) and
MDA-MB-468 cells did not express plexD1 mRNA at all (Fig. 1,
C–D). The expression of the neuropilins and of the mRNA
encoding the sema3E receptor PlexD1 in the various tumor cells
was not altered significantly as a result of the expression of the
various recombinant semaphorins ( Figs. S1 and S2).
The effects of different sema3s on the development of
tumors from cancer cells
To find out if sema3A, sema3D, sema3E, sema3F or sema3G
over-expression can affect the development of tumors from
different tumorigenic cell lines, we expressed the full length
cDNAs encoding the five semaphorins or an empty control vector
in the tumor cells using a lentiviral expression vector that confers
resistance to puromycin. Pools of infected cells were examined for
semaphorin expression following puromycin selection using
antibodies directed against epitope tags incorporated into the
recombinant semaphorins. The expression levels of the recombi-
nant semaphorins seemed to differ in correlation with the type of
the recombinant semaphorin and much less so in correlation with
the cell type in which they were expressed. Thus, the
concentration of recombinant sema3D found in the conditioned
medium of either MDA-MB-231 breast cancer cells or in MDA-
MB-435 melanoma cells was significantly lower than the
concentrations of sema3F or sema3G (Fig. 2, A–B). It was not
possible to effectively compare the concentrations of the
endogenous semaphorins produced by the tumor cells with the
concentrations of the recombinant semaphorins expressed in each
of the cell types due to the lack of suitable highly specific
antibodies directed against the various semaphorins. However,
from reverse transcription followed by PCR (RT-PCR) experi-
ments it is clear that the various tumor cells we studied also express
various endogenous mRNA’s encoding class-3 semaphorins
suggesting that these cells may produce combinations of
endogenous semaphorins. Thus, MDA-MB-435 cells express
mRNA encoding sema3D while MDA-MB-231 cells express
sema3A and sema3E mRNA while MCF-7 and MDA-MB-468
cells express mRNA encoding sema3F (Fig. 2C).
Sema3s contain conserved cleavage sites for furin like pro-
protein convertases[23]. In the case of sema3E the cleaved product
was reported to possess pro-metastatic properties [24]. However,
the degree of cleavage of the recombinant semaphorins produced
by MDA-MB-231 cells or by MDA-MB-435 cells did not exceed
15% of the total amount of semaphorin found in the conditioned
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not shown). The cells were subsequently implanted in mammary
fat pads of immune deficient mice, and allowed to form tumors.
All these semaphorins were relatively efficiently expressed in
MDA-MB-231 cells although there were substantial differences in
the expression levels obtained with different semaphorins (Fig. 2A).
Expression of the np1 agonist sema3A [25] inhibited almost
completely the development of tumors from these cells (Fig. 3, A–B
and Fig. S3, A). Sema3D, an agonist for both np1 and np2 [26],
inhibited tumor formation completely in one experiment (data not
shown) and in another experiment inhibited strongly though not
completely tumor development even though it was not as highly
expressed as the other semaphorins (Fig. 3, E–F). In contrast, the
np2 agonist sema3G [27] was unable to inhibit tumor develop-
ment from these cells, although it was highly expressed as
compared to sema3D (Fig. 3, G–H). The np2 agonist sema3F on
the other hand, inhibited significantly the development of tumors
despite the lack of np2 receptors in MDA-MB-231 cells (Fig. 3, A–
B). The tumors that developed from sema3F expressing MDA-
MB-231 cells (Fig. 3, A–B) looked less bloody than the control
tumors suggesting that sema3F may inhibit tumor angiogenesis
(Fig. S3, A). Expression of the PlexD1 agonist sema3E [9] also
inhibited significantly the development of tumors from these cells
but the resulting tumors did not look starved of blood vessels
(Fig. 3, C–D, and Fig. S3, B).
A different picture emerged when the effects of these sema3s on
the development of tumors from MDA-MB-435 cells were
examined. Control cells developed into small tumors that slowed
when they reached an average volume of 50–100 mm
3 (Fig. 3, A–
B). Expression of the np2 agonists sema3F and sema3G strongly
inhibited the development of tumors from these cells (Fig. 4, A–D).
In contrast, expression of sema3A did not inhibit tumor
development (Fig. 4, A–B), while sema3D which binds to both
neuropilins [26], significantly inhibited tumor development from
the MDA-MB-435 cells though less potently than sema3G (Fig. 4,
C–D) which may be due to the lower expression levels obtained
with sema3D in these cells (Fig. 2B). MDA-MB-435 cells also
express the PlexD1 mRNA, although at lower levels than MDA-
MB-231 cells (Fig. 1C). Expression of sema3E did not inhibit the
formation of tumors from the MDA-MB-435 cells (Fig. 4 C–D).
This was probably not due to cleavage by furin like pro-protein
convertases since less than 5% of the sema3E found in the
conditioned medium of these cells was cleaved (data not shown).
We also determined whether expression of sema3A and
sema3F, the best studied np1 and np2 agonists respectively,
inhibits tumor development from the non-metastatic, estrogen
dependent, np1 expressing MCF-7 cells. Expression of sema3A
inhibited significantly tumor development while expression of
sema3F did not (Fig. 5, B–C). Taken together, these results
suggested that the sema3s ability to inhibit tumor formation from a
given cancer cell type depends primarily on the identity of the
semaphorin receptors expressed by the tumor cells, suggesting that
sema3s should not be able to inhibit the formation of tumors from
cancer cells that do not express sema3 receptors (Table 1).
To put this prediction to the test we expressed sema3A and
sema3F in MDA-MB-468 breast cancer cells, which do not
Figure 1. Expression of semaphorin receptors in different tumorigenic cell lines. (A) Cells were grown to 80% confluence and lysed. Equal
amounts of protein were loaded and separated on SDS/PAGE gels and subsequently blotted on nitrocellulose filters. Western blot analysis of np1 and
np2 was performed as described in materials and methods. (B) Densitometric analysis of three independent experiments showing the relative
expression levels of np1 in MDA-MB-231 and MCF-7 cells was preformed using the MultiGauge software. The average expression level of np1 in the
MCF-7 cells was taken as 100% and the average expression level of np1 in the MDA-MB-231 cells was compared to the average expression level in
MCF-7 cells. (C, D) Reverse PCR analysis of the expression of mRNA’s encoding plexA1-A4 and plexD1 was performed according to the instruction of
the PerfectPure kit using primer pairs specific to the different plexins as described.
doi:10.1371/journal.pone.0003287.g001
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growing tumors in mammary fat pads of nu/nu balb/c mice. In
agreement with our prediction, neither the expression of
recombinant sema3A nor expression of sema3F significantly
inhibited the formation of tumors from these cells (Fig. 5, E–F).
The effects of different sema3s on tumor angiogenesis
Sema3F was characterized in several studies as an inhibitor of
tumor angiogenesis and as a repulsive factor for endothelial cells
[15,16,28] and sema3A was also found to function as an inhibitor
of VEGF induced angiogenesis and as a repulsive factor for
endothelial cells although not as an inhibitor of tumor angiogenesis
[17,19,29,30]. To compare the repulsive properties of different
sema3s we seeded HEK293 cells secreting different semaphorins
on top of monolayers of human umbilical vein endothelial cells
(HUVEC) at clonal densities. Control cells infected with empty
vector did not repel endothelial cells while sema3A, sema3D and
sema3E expressing cells repelled endothelial cells efficiently
(Fig. 6A). However, the np2 agonists sema3F and in particular
sema3G repelled HUVEC much less potently than the np1
agonists or the PlexD1 agonist sema3E, possibly because these cells
contain about 3 fold less np2 as compared to np1 [5] (data not
shown). We therefore seeded HEK293 cells expressing either
sema3F or sema3G on top of porcine aortic endothelial (PAE) cells
Figure 2. Determination of the relative concentrations of recombinant class-3 semaphorins secreted into the conditioned medium
of MDA-MB-231 and MDA-MB-435 cells. Lentiviruses containing the full length cDNAs encoding five semaphorins and a puromycin resistance
cassette or empty control lentiviruses were used to infect MDA-MB-231 and MDA-MB-435 cells. Sema3A has a flag epitope tag, whereas the rest of
the semaphorins were labeled with a myc epitope tag. (A, B) Western blot analysis of equal aliquots of conditioned medium derived from equal
numbers of MDA-MB-231 and MDA-MB-435 cells expressing the different sema3s. The expression levels of all the myc tagged semaphorins was
quantified as described in materials and methods. (C) Reverse PCR analysis of endogenous mRNA’s encoding sema3A, sema3D, sema3E, sema3F and
sema3G expression was performed according to the instruction of the PerfectPure kit using primer pairs specific to the different semaphorins as
described. MDA-MB-231 cells over-expressing the different recombinant semaphorins were used as positive controls.
doi:10.1371/journal.pone.0003287.g002
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expected, these cells were repelled very strongly by sema3F.
Surprisingly they were repelled much less potently by sema3G
suggesting that plexA1 may not be able to transduce sema3G
signals (Fig. 6B).
To find out if the various sema3s inhibit tumor angiogenesis, we
determined the concentration of blood vessels in tumors that
developed from control or from sema3s expressing cells. Since
sema3A inhibited tumor formation in MDA-MB-231 cell almost
completely we could not determine the concentration of blood
vessels in this case. However, expression of sema3D in MDA-MB-
231 cells resulted in the formation of tumors containing a 40%
lower density of blood vessels as compared to tumors that
developed from control cells (Fig. 6C). The reduction in the
concentration of tumor associated blood vessels was not correlated
with the types of semaphorin receptors expressed by the cancer
cells since expression of the np2 agonists sema3F and sema3G also
reduced the concentration of blood vessels in tumors derived from
MDA-MB-231 cells by about 40% (Fig. 6C) even though sema3G
did not inhibit the development of tumors from these cells (Fig. 3,
G–H). In-contrast, even though sema3E expression in MDA-MB-
231 cells significantly inhibited the development of tumors
(Fig. 3D) and even though sema3E expressing cells repulse
HUVEC efficiently (Fig. 6A) the expression of sema3E in these
cells did not reduce significantly the concentration of blood vessels
in resulting tumors (Fig. 6C).
We also examined the effects of sema3A and sema3F expression
on the concentration of tumor associated blood vessels in MCF-7
cells. These tumors develop in the mammary fat pads of the mice
only in the presence of slow estrogen release pellets. Expression of
sema3A in these cells significantly reduced the concentration of
tumor associated blood vessels. However, expression of sema3F
did not (Fig. 6D). The lack of inhibition in this case may perhaps
be explained by findings suggesting that estrogen is an inhibitor of
np2 expression [31].
In the case of tumors that develop from np2 expressing MDA-
MB-435 cells, we found that the expression of sema3A and
sema3D reduced the concentration of blood vessels in resulting
tumors by 65% (Fig. 6E) even though tumor development from
these cells was not inhibited at all by sema3A (Fig. 3B). It was not
possible to determine the blood vessel concentration in tumors that
developed from cells expressing sema3F or sema3G since the
resulting tumors were too small or non-existent as in the case of
sema3G. Expression of sema3E in MDA-MB-435 cells produced a
small but significant 28% decrease in the concentration of blood
vessels in resulting tumors even though tumor formation from
these cells was not inhibited by sema3E (Fig. 4D).
Taken together, these experiments indicate that although most
of the semaphorins are able to inhibit tumor angiogenesis as
manifested by the reduction in the concentration of blood vessels
in tumors in response to the expression of recombinant
semaphorins. However, even though the inhibition may contribute
to the inhibition of tumor progression, there was generally no
correlation between the effects of the sema3s on tumor
angiogenesis and their effect on tumor development (Table 1).
The effects of different sema3s on the behavior of the
tumor cells in-vitro
The experiments described in the previous sections suggest that
semaphorin expression should modulate the behavior of tumor
Figure 3. The effect of the expression of different sema3s on the development of tumors from MDA-MB-231 cells. MDA-MB-231 cells
infected with control lentivirus or infected with lentiviruses directing expression of five different semaphorins were implanted in the mammary fat
pads of balb\c nu/nu mice as described. (A, C, E, G) The average volume of the developing tumors was measured as a function of time after
implantation as described in materials and methods. (B, D, E, F) The average weight of the tumors at the end of the experiment was determined as
described in materials and methods.
doi:10.1371/journal.pone.0003287.g003
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to inhibit the adhesion, spreading and proliferation of various
types of tumor cells [13,16,18]. However, the proliferation of the
tumor cell types which we have used in the present study was not
inhibited as a result of the expression of the various semaphorins
when the tumor cells were grown in tissue culture dishes (data not
shown). We also examined the effect of the expression of the
different semaphorins on the adhesion of the various tumor cells to
plastic or to fibronectin. However, none of these semaphorins
affected the adhesion of the tumor cells regardless of whether the
substrate was plastic or fibronectin (data not shown).
The ability to form colonies in soft-agar is a hallmark that
differentiates many types of cancer cells from their normal
counterparts [32–34]. We therefore determined if the expression
of different class-3 semaphorins in MDA-MB-231 or MDA-MB-
435 cells affects their ability to form colonies in soft-agar. None of
the semaphorins inhibited completely the formation of colonies by
MDA-MB-231 cells. However, the expression of sema3A and
sema3D, semaphorins that strongly inhibited tumor formation
from these cells (Fig. 3), also inhibited significantly the formation of
large colonies in soft agar (Fig. 7, A–B). Surprisingly, expression of
sema3F also inhibited significantly the formation of large colonies
in soft agar despite the absence of np2 receptors on these cells.
However, the expression levels of sema3F were the highest of all
the semaphorins we examined (Fig. 2A) and sema3F was also able
to inhibit the formation of tumors from these cells (Fig. 3B).
Sema3F binds to np1, albeit with a 10 fold lower affinity as
compared to its binding affinity to np2 [35] and there is one
additional report suggesting that it may also utilize np1 for signal
transduction [36]. It is therefore possible that this inhibitory effect
is mediated by np1. Another np2 agonist, sema3G, which in
contrast with sema3F does not inhibit the development of tumors
from MDA-MB-231 cells (Fig. 3H) and does not bind to np1 [37],
had no effect on the development of colonies from these cells
(Fig. 7A). MDA-MB-231 cells also express the sema3E receptor
PlexD1 and expression of sema3E inhibits the formation of tumors
from these cells (Fig. 3D). However, sema3E failed to inhibit the
formation of colonies from MDA-MB-231 cells (Fig. 7, A–B).
We also determined whether sema3D, sema3F and sema3G,
which inhibit tumor formation from MDA-MB-435 cells (Fig. 4),
Figure 4. The effect of the expression of different sema3s on the development of tumors from MDA-MB-435 cells. MDA-MB-435 cells
infected with control lentivirus or infected with lentiviruses directing expression of five different semaphorins were implanted in the mammary fat
pads of balb\c nu/nu mice as described. (A, C) The average volume of the developing tumors was measured as described in materials and methods.
(B, D) The average weight of the tumors at the end of the experiment was determined as described in materials and methods.
doi:10.1371/journal.pone.0003287.g004
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and sema3G inhibited colony formation efficiently as expected.
However, to our surprise we found that sema3F did not, even
though it did inhibit almost completely the formation of tumors
from these cells (Fig. 7, C–D). Another unexpected observation
was that sema3E, which did not inhibit the formation of tumors
from these cells was able to inhibit colony formation (Fig. 7, C–D).
Lastly, we expected that sema3A will not affect colony formation
since its receptor is not expressed by MDA-MB-435 cells (Fig. 1).
Surprisingly, we found that not only was colony formation not
inhibited but it was even significantly enhanced (Fig. 7, C–D).
Taken together our results suggest that despite a number of
exceptions, in most cases inhibition of tumor growth by sema3s is
correlated with their ability to inhibit the formation of soft agar
colonies from the tumor cells (Table 1).
Enhancement of tumor development from MDA-MB-435
cells by np1 expression is inhibited by co-expression of
sema3A
The experiments described above suggest that the expression of
specific sema3s receptors by tumor cells is probably the most
important factor that determines whether a given sema3 will
function as an inhibitor of tumor development. To test this
hypothesis further we expressed np1 in MDA-MB-435 cells in
order to determine whether this would render tumors that develop
Figure 5. The effect of the expression of different sema3s on the development of tumors from MCF-7 and MDA-MB-468 cells. MCF-7
and MDA-MB-468 cells infected with control lentivirus or infected with lentiviruses directing expression of five different semaphorins were implanted
in the mammary fat pads of balb\c nu/nu mice as described. (A, D) Western blot analysis of aliquots of conditioned medium derived from equal
numbers of cells infected with empty lentiviruses (C) or with different sema3s (s3X) as indicated. (B, E) The average volume of the developing tumors
was measured as described in materials and methods. (C, F) The average weight of the tumors at the end of the experiment was determined as
described in materials and methods.
doi:10.1371/journal.pone.0003287.g005
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from MDA-MB-435 cells expressing np1 grew very rapidly to a
much larger size than tumors derived from empty vector infected
MDA-MB-435 cells following an initial lag (Fig. 8, A–C).
Interestingly, the density of blood vessels within these tumors
was not significantly different from that of control tumors (Fig. 8D).
When the np1 agonist sema3A was co-expressed in these cells
along with np1, the cells that expressed both genes reverted to the
behavior exhibited by the control cells and formed slowly
developing tumors thereby eliminating the growth advantage
conferred by the presence of np1 (Fig. 8, A–C), but not that
conferred by the presence of np2 which can be further inhibited by
np2 agonists such as sema3F or sema3G (Fig. 4). Interestingly, the
density of blood vessels in tumors that developed from MDA-MB-
435 cells expressing sema3A or sema3A/np1 was similar and
about 50% lower than the concentration of blood vessels in tumors
that developed from control cells (Fig. 8D). These results also
suggest independently that inhibition of angiogenesis may
represent part of the mechanism by which semaphorins modulate
tumor progression, but that it may not always be sufficient to
inhibit tumor growth.
Discussion
The identification of sema3B and sema3F as tumor suppressors
[13,14,38], and the identification of sema3F and sema3A as
inhibitors of angiogenesis [15,39], suggested that additional
sema3s may also possess anti-tumorigenic and anti-angiogenic
properties. We show here for the first time that sema3A, sema3D,
sema3E and sema3G display anti-tumorigenic properties. Fur-
thermore, we show that all of these class-3 semaphorins can also
inhibit tumor angiogenesis.
Many tumorigenic cell lines, including the cell lines we used,
express different combinations of neuropilins and plexins [40].
Neuropilins as well as several types of plexins are also expressed in
endothelial cells [19] and in some bone marrow derived cells [41]
which are frequently recruited into the tumor microenvironment.
Complexes formed between the neuropilins and several types of
plexins mediate sema3s induced signal transduction with the
exception of sema3E which signal through PlexD1 independently
of neuropilins [2]. Our initial experiments suggested that the
expression of given semaphorins in tumor cells sometimes
inhibited and sometimes did not inhibit the development of
tumors from different types of tumor cells.
To better understand these seemingly conflicting results we
compared the effects of the expression of several semaphorins on
the development of tumors from tumorigenic cell lines differing in
their expression pattern of semaphorin receptors so as to find out if
we can identify a property that can predict whether a given
semaphorin will be able to inhibit the development of tumors from
a given type of tumor cell. The expression of the different
recombinant semaphorins in the tumor cells did not change
significantly the expression of the primary semaphorin binding
receptors np1, np2 and PlexD1 in the tumor cells. Therefore,
observed differences in responses to the expression of different
semaphorins in the tumor cells were not due to semaphorin
induced changes in the expression of direct semaphorin receptors.
Semaphorin signaling through these receptors may also be
modulated by changes in the expression levels of endogenous
semaphorins and by changes in the expression and activity of
neuropilin associated receptors such as additional types of plexins
and adhesion receptors known to modulate semaphorin signal
transduction [2] which are present on tumor cells as well as on
tumor associated stromal cells such as endothelial cells. We have
Table 1. Summary of the results.
Cell line
Expression of
recombinant
semaphorin
Known
binding
receptors
Expression of semaphorin
receptors in tumor cells
Inhibition of
tumor
development
Inhibition of
angiogenesis
Inhibition of soft agar
colony formation
NP1 NP2 PlexD1**
MDA-MB-231 S3A NP1 +++ +++ 3 N.D.* 3
S3D NP1, NP2 333
S3E PlexD1 3 NO NO
S3F NP1, NP2 ***33 3
S3G NP2 NO 3 NO
MDA-MB-435 S3A NP1 +++ + NO 3 NO
S3D NP1, NP2 333
S3E PlexD1 NO 33
S3F NP1, NP2 3 N.D.* NO
S3G NP2 3 N.D.* 3
MCF-7 S3A NP1 ++ +++ 33N.D.
S3F NP1, NP2 NO NO N.D.
MDA-MB-468 S3A NP1 NO NO N.D.
S3F NP1, NP2 NO NO N.D.
The effects of the expression of the semaphorins in the four tumor cell lines on tumor development, tumor angiogenesis and on the anchorage free growth of the cells
are summarized. The relative expression levels of the relevant semaphorin binding receptors in each of the cell lines are shown as well (High level expression: +++,L o w
level expression: +). N.D., not determined.
*MDA-MB-231 derived tumors expressing sema3A and tumors derived from MDA-MB-435 expressing sema3F and sema3G did not develop and it was therefore not
possible to measure effects on tumor angiogenesis.
**Estimation of the relative expression levels of plexD1 is based on estimation of mRNA levels.
***Sema3F binds to np1 with a 10 fold lower affinity as compared to its affinity for np2 but it is unclear whether np1 can transduce sema3F signals.
doi:10.1371/journal.pone.0003287.t001
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appropriate specific antibodies directed against these different
proteins and because of the large volume of assays required to
monitor such changes systematically.
Regardless of these possible modulating influences, we have
found that the expression of a semaphorin receptor able to bind
the specific recombinant semaphorin we expressed in the tumor
cells was the property that correlated best with the ability to
successfully inhibit tumor development (Table 1). There were only
two cases in which this correlation did not successfully predict
whether a specific semaphorin will be able to inhibit tumor
development from a given type of tumor cell. In the first such
example Sema3E was not able to inhibit tumor development from
MDA-MB-435 cells. However, the expression levels of the mRNA
encoding the sema3E receptor plexD1 in the MDA-MB-435 cells
are lower than their levels in MDA-MB-231 cells which may
perhaps account for the discrepancy. The second example was the
successful inhibition by sema3F of tumor formation from MDA-
MB-231 cells which express np1 but not np2 and thus should not
have been inhibited by sema3F. However, the concentration of
np1 in these cells is relatively high [4]. Sema3F is known to bind to
np1 with a 10 fold lower affinity as compared to np2. Even though
sema3F is usually viewed a pure np2 agonist there is nevertheless
some evidence suggesting that sema3F may be able to transduce
signals using np1 [36]. It is thus possible that the inhibition of
tumor development from MDA-MB-231 cells by sema3F is
mediated by np1 and that it is augmented by the relatively high
expression level obtained with sema3F and by the anti-angiogenic
effect displayed by sema3F in tumors derived from this cell type.
The lack of an anti-tumorigenic effect of sema3F in tumors
developing from sema3F expressing MCF-7 cells which also
express np1 but no np2 may be explained by the lower
concentration of np1 receptors in these cells and by the absence
of a sema3F induced anti-angiogenic effect which is probably the
result of np2 down regulation in endothelial cells of blood vessels
due to the effects of prolonged estrogen administration [31].
In order to determine whether there is a correlation between the
anti-angiogenic activity of specific semaphorins and their ability to
Figure 6. Different sema3s repel endothelial cells in-vitro and reduce the density of tumor associated blood vessels in-vivo. (A)
Control HEK293 cells infected with an empty lentiviral vector or HEK293 cells expressing sema3A, sema3D or sema3E were seeded on top of a
monolayer of HUVEC cells as described in materials and methods. The HEK293 cells were labeled with the fluorescent vital dye DIasp prior to seeding.
Shown are composite pictures taken by phase and fluorescent microscopy. (B) Control HEK293 cells infected with an empty lentiviral vector or
HEK293 cells expressing sema3F or sema3G were seeded on a monolayer of PAE cells expressing np2 and plexA1 as described in materials and
methods. The HEK293 cells were stained with DIasp and photographed as described in material and methods (C) The average area of blood vessels
per microscopic field was determined in sections derived from tumors that developed from MDA-MB-231 cells infected with empty lentiviruses or
from MDA-MB-231 cells expressing different sema3s as described in materials and methods. Since the tumors that did develop from sema3A
expressing cells were extremely small (Fig. 3) we could not determine the density of blood vessels in them. (D) The average area of blood vessels per
microscopic field was determined in tumors derived from control MCF-7 cells or from MCF-7 cells expressing sema3A or sema3F as described in
material and methods. (E) The average area of blood vessels per microscopic field was determined in tumors that developed from control MDA-MB-
435 cells or from MDA-MB-435 cells expressing different sema3s as described in material and methods. No tumors developed from sema3G and
sema3F expressing MDA-MB-435 cells (Fig. 4).
doi:10.1371/journal.pone.0003287.g006
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expression of several semaphorins in several tumor cell types on
the concentration to tumor associated blood vessels. We have
presented here for the first time evidence indicating that sema3D,
sema3G sema3E and sema3A can significantly reduce the
concentration of microvessels in tumors that develop from tumor
cells that express these semaphorins. Surprisingly, we found that
reduction in the concentration of tumor associated blood vessels
was frequently not correlated with the anti-tumorigenic effect of
given semaphorins. For example, even though sema3G and
sema3A expression did not inhibit at all the development of
tumors from MDA-MB-231 and MDA-MB-435 cells respectively,
they nevertheless strongly reduced the concentration of tumor
associated blood vessels. These observations indicates that
inhibition of tumor angiogenesis by the sema3s we examined
was probably not sufficiently effective to affect tumor growth. Anti-
VEGF antibodies were reported to reduce the concentration of
blood vessels in MDA-MB-231 derived tumors by as much as 70%
[42,43] while individual sema3s reduced blood vessel densities in
such tumors by up to 40%. It is of course rather difficult to
compare two different studies in which the methods used to
evaluate blood vessel density were not identical. Nevertheless, it is
likely that the anti-angiogenic effects of individual sema3s were not
sufficiently strong so as to enable inhibition of tumor development
in the case of the cancer cells that we examined. It is however
likely that the anti-angiogenic effects of the semaphorins will
assume more importance in the case of rapidly growing tumors
that may be more dependent on efficient angiogenesis than slowly
growing tumors. We have previously shown that combinations of
sema3s that interact with different semaphorin receptors can
inhibit the proliferation of endothelial cells more effectively than
individual sema3s [19]. Our results suggest that combinations of
such sema3s may perhaps be able to increase the anti-angiogenic
effects to the point at which they may affect tumor development
more effectively.
Another parameter we have examined as a possible predictor
for the effectiveness of class-3 semaphorins as anti-tumorigenic
agents was effects of class-3 semaphorin expression in tumor cells
on the behavior of the tumor cells in-vitro. Contrary to previous
reports which observed sema3F and sema3A induced changes in
adhesion of tumor cells to fibronectin coated dishes [16,18,44], we
could not see any effects of any of the semaphorins we tested on
the adhesion to fibronectin of any of the tumor cells used here. We
also could not detect any effects of semaphorin expression in the
Figure 7. Different sema3s inhibit the formation of soft agar colonies from MDA-MB-231 or MDA-MB-435 cells. (A) Single cell
suspensions of control MDA-MB-231 cells or MDA-MB-231 cells expressing different sema3s were seeded in soft agar as described in materials and
methods. Colonies were allowed to form for 21 days. The colonies were then stained with crystal violet and microscopic fields photographed. The
average colony area of colonies with a diameter exceeding 150 mm was then determined as described in materials and methods. (B) Photographs of
representative microscopic fields containing crystal violet stained colonies that developed in soft agar from control MDA-MB-231 cells or from MDA-
MB-231 cells expressing the indicated sema3s. (C) The formation of colonies in soft agar from control MDA-MB-435 cells or from MDA-MB-435 cells
expressing the indicated sema3s was determined as described in materials and methods. (D) Photographs of representative microscopic fields
containing crystal violet stained colonies that developed in soft agar from control MDA-MB-435 cells or from sema3s expressing MDA-MB-435 cells.
doi:10.1371/journal.pone.0003287.g007
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regular 2D cell culture. This observation contrasts with the strong
effects observed when using cultured endothelial cells [19].
However, some of the semaphorins we used inhibited the growth
of colonies of tumor cells in soft agar. The correlation between the
ability to inhibit the growth of colonies in soft-agar and the anti-
tumorigenic effects of the semaphorins was better than the
correlation with the anti-angiogenic effects of the semaphorins,
but it was nevertheless a less reliable predictor for the effectiveness
of the semaphorins as anti-tumorigenic agents as compared with
the presence of appropriate semaphorin receptors in the tumor
cells. For example, sema3F did not inhibit the formation of
colonies from MDA-MB-435 cells despite the presence of np2
receptors in these cells even though it inhibited strongly tumor
formation. In contrast, sema3E inhibited strongly the formation of
soft-agar colonies from MDA-MB-435 cells but did not inhibit the
formation of tumors. Nevertheless, in most cases the ability to
inhibit the formation of colonies in soft agar was correlated with
the ability to inhibit the development of tumors in-vivo.
The presence of appropriate signaling semaphorin receptors on
tumor cells does not necessarily imply that the anti-tumorigenic
effects observed are due to direct effects on the tumor cells, even
though in some cases that may be the case. There is some evidence
indicating that neuropilins may be able to associate with receptors
present on adjacent cells ‘‘in-trans’’ [45] and it is also possible that
the final outcome in-vivo will depend on the effects of secondary
effectors synthesized in response to semaphorins in responsive
tumor cells, resulting in different responses in-vivo as compared to
in-vitro experiments in which the only cell type is the tumorigenic
cell. An example for such a modulator of semaphorin function is
provided by the furin like pro-protein convertases, which are
strongly up-regulated in cancer cells [46]. The furins cleave class-3
semaphorins at a conserved site and the cleavage results in inactive
products in the case of sema3A and sema3B [23,47]. In the case of
sema3E the cleavage generates a pro-metastatic product that
affects primarily endothelial cells rather than tumor cells [24] and
is thus an example for an effect that will be seen only in-vivo but will
not affect in-vitro assays such as the soft-agar colony formation
assay. It should be noted that in our experiments the maximal
amount of cleavage by pro-protein convertases never exceeded
15% of the total amount of sema3s found in the conditioned
medium of producing tumor cells, and in the case of sema3E the
cleavage was almost undetectable in both MDA-MB-231 and
MDA-MB-435 cells, suggesting that the inhibitory effects that we
observed are due to the effects of full length sema3E.
In conclusion, we have found for the first time that the
semaphorins sema3A, sema3D, sema3E and sema3G possess anti-
tumorigenic and anti-angiogenic properties similar to those
Figure 8. Expression of np1 in MDA-MB-435 cells enhances the growth of resulting tumors and sema3A abrogate the enhancing
effect. (A) A western blot comparing the expression of np1 in MDA-MB-435 cells infected with lentivirus directing expression of np1, sema3A or an
empty vector is shown at the top. The average volumes of the tumors that developed following the implantation of these cells in mammary fat pads
of nude mice as a function of time after implantation is shown in the lower part. (B) Photographs of tumors excised at the end of the experiment. (C)
The average weight of the tumors at the end of the experiment was determined as described in materials and methods. (D) The average area of
blood vessels/microscopic field in tumor sections was determined as described in materials and methods.
doi:10.1371/journal.pone.0003287.g008
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However, the anti-angiogenic effects are probably not sufficiently
potent so as to enable inhibition of tumor development. The anti-
tumorigenic effect of sema3s seems to be associated with the
expression of appropriate sema3s receptors by the tumor cells
although it is not clear if all the anti-tumorigenic effects are due to
direct effects on the tumor cells. Our results argue that for
maximal effectiveness, the selection of specific semaphorins or
semaphorin combinations will have to take into account the
identity of the semaphorin receptors expressed by the tumorigenic
cells within target tumors.
Supporting Information
Figure S1 The endogenous expression levels of NP-1, NP-2 and
PlexD1 in MDA-MB-231 and MDA-MB-435 cells infected with
lentiviruses directing the expression of different class-3 semaphor-
ins. Cell lysates were prepared from MDA-MB-231 (panel A) and
MDA-MB-435 (panel-B) cells infected with lentiviruses directing
the expression of the indicated class-3 semaphorins or an empty
lentiviral expression vector. The expression levels of NP-1 (Aa, Ba)
and NP-2 (Ab, Bb) in the respective cell types were compared
using western blot analysis as described in materials and methods.
The expression of Plex-D1 (Ac, Bc) was detected by RT-PCR as
described in Fig. 1.
Found at: doi:10.1371/journal.pone.0003287.s001 (6.76 MB TIF)
Figure S2 The endogenous expression of NP-1, NP-2 and
Plexin-D1 in MCF-7 and MDA-MB-468 infected with lentiviruses
directing expression of sema3A or sema3F. Cell lysates were
prepared from MCF-7 (panel-A) or MDA-MB-468 (panel-B) cells
infected with control lentiviruses or lentiviruses directing expres-
sion of sema3A or sema3F. The expression of NP-1 (Aa, Ba) and
NP-2 (Ab, Ba) was detected using western blot analysis as
described in materials and methods. The expression levels of the
Plex-D1 mRNA in the two cell types (Ac, Bb) was detected by RT-
PCR as described in materials and methods.
Found at: doi:10.1371/journal.pone.0003287.s002 (4.79 MB TIF)
Figure S3 Photographs of excised tumors derived from MDA-
MB-231 cells expressing sema3A, sema3F, sema3E and an empty
expression vector. Control MDA-MB-231 cells infected with
empty lentiviruses (C) or MDA-MB-231 cells expressing recom-
binant sema3A (S3A) sema3F (S3F) or sema3E (S3E) were
implanted in the mammary fat pads of balb\c nu/nu mice as
described. At the end of the experiment tumors were excised and
photographed.
Found at: doi:10.1371/journal.pone.0003287.s003 (4.93 MB TIF)
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